Navigation Links
Robert G. Savage, Former Worldwide Chairman, Johnson & Johnson's Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
Date:9/10/2012

MIAMI, Sept. 10, 2012 /PRNewswire/ -- Nuovo Biologics, LLC announced that Robert G. Savage has joined its Board. Mr. Savage served as Group Vice President and President – General Therapeutics & Inflammation Business of Pharmacia Corporation from 2002 until its acquisition by Pfizer, Inc. in 2003.  From 1996 through 2001, Mr. Savage served Johnson & Johnson in a variety of roles, most recently as Worldwide Chairman of Johnson and Johnson's Pharmaceutical Group.  From 1985 to 1996 he served Roche Holding AG in a variety of senior marketing, business development and operations positions, most recently as Vice President – Marketing, Hoffman-La Roche, Inc.  He is currently a director of EpiCept Corporation and The Medicines Company.  Mr. Savage was a member of the Board of Directors of Noven Pharmaceuticals, Inc. from 2004 until 2009 when the company was sold to Hisamitsu Pharmaceuticals Company.  Mr. Savage has been the President of Strategic Imagery LLC, a pharmaceutical consultancy, since 2003. 

Donald A. Denkhaus, Chairman of the Board of Nuovo Biologics stated, "We are exceptionally fortunate to have a pharmaceutical executive with such a wealth of experience join our Board.  Bob's leadership, strategic vision and marketing experience will help move our company to the next level." 

Dr. Jay Yourist, CEO said, "Nuovo's first drug in the U.S. will be a broad spectrum antiviral to treat companion animals. Ultimately, approval for human uses for our drugs will be sought. We are particularly pleased that Bob is joining our Board, especially in light of his past responsibility of developing and launching several antiviral and anti-bacterial drugs including Rocephin (ceftriaxone) and Tamiflu (oseltamivir) while he was at Roche and Levaquin (levofloxacin) while he was at Johnson & Johnson."  Tamiflu is currently a leading antiviral drug with billions in sales globally since its launch.

Nuovo Biologics, LLC is a Florida based biopharmaceutical company that is pursing innovative health products and technologies.


'/>"/>
SOURCE Nuovo Biologics, LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
2. PAREXEL International to Present at Robert Baird Healthcare Conference
3. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
4. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
5. ReShape Medical Appoints Robert E. Grant to Board of Directors
6. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
7. Mike Golic, ESPN Radio Personality and Former Philadelphia Eagle, Holds Pre-Season "Training Camp" for People With Type 2 Diabetes
8. Par Formulations (Formerly Edict Pharmaceuticals) Receives First ANDA Approval
9. Phonak and Special Olympics join forces with US Olympian, former Congressman Jim Ryun
10. Judge Upholds $3.3 Million Judgment In Favor of Fox Insurance Company Against Former Pharmacy Benefit Manager
11. Former NxStage Patient Nikolas Gieske Celebrates Kidney Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. ... focused on the design, manufacture, sale and distribution of ... on the progress of its commercial roll-out in ... available in more than one hundred (100) medical institutions ... AeroForm offers a needle-free alternative for women who ...
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... June 3, 2017  Eli Lilly and Company ... results from the Phase 3 MONARCH 2 study ... 6 inhibitor, in combination with fulvestrant, significantly improved ... alone in women with hormone-receptor-positive (HR+), human epidermal ... who have relapsed or progressed after endocrine therapy ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... ... As a leading dental practice, Wall Centre Dental supports Stroke Awareness Month ... bleeding gums in Vancouver, BC, may be developing gingivitis, the first stage of ... and diabetes. Drs. Parviz Roshan, Siamak Tehrani and Milton Reskovich offer laser gum therapy ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants in the ... finding product improvements that could reduce the occurrence of unplanned extubations (UEs). ... breathing or to provide medication. Sometimes, patient movement can cause unplanned extubations which ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage ... featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA Flex ... cotton easy care stretch twill. , With trendy looks hitting the medical community, UA ...
(Date:6/20/2017)... ... , ... John D'Eri, CEO of Rising Tide Car Wash , will ... during the Autism Society of America 's 49th annual conference to be held ... (DJFF) was founded in 2002 as the nation's first autism organization focused exclusively ...
(Date:6/20/2017)... ... June 20, 2017 , ... International water ... The Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health ... world’s water crisis and how it affects the human eyes. , According ...
Breaking Medicine News(10 mins):